Thus, inhibiting glycolysis by increasing FBP1 expression may play a crucial role in improving cisplatin sensitivity, and combination therapies targeting the glycolytic pathway are promising for the treatment of chemoresistant cancer cells. Here, FBP1 is linked to cancer.